The phase 3 program missed both primary and key secondary endpoints, with no statistically significant effects on relevant measures observed for patients receiving investigational treatment ...

Percheron Therapeutics board addresses shareholders following failed phase 2b trial EBR’s US FDA manufacturing pre-approval inspection scheduled to start January 14 as share price rockets Regis ...